The Technical AnalystExchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Lupin Limited Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.34% INR1 616.15
America/New_York / 8 mai 2024 @ 05:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 736 560 mill |
| EPS: | 41.88 |
| P/E: | 38.59 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 455.75 mill |
| Avg Daily Volume: | 1.173 mill |
| RATING 2024-05-08 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 38.59 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 38.59 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
INR230.09 (-85.76%) INR-1 386.06 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
INR 1 577.34 - 1 654.96 ( +/- 2.40%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | INR1 616.15 (0.34% ) |
| Volume | 1.693 mill |
| Avg. Vol. | 1.173 mill |
| % of Avg. Vol | 144.28 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LUPIN.NS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LUPIN.NS
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.